Key clinical point: Poorly controlled asthma during pregnancy was linked with worse outcomes.
Major finding: The live birth rate was 68% in women with poorly-controlled asthma, 71% with well-controlled asthma, and 74% without asthma.
Study details: Review of private-insurance claims data from 1,026,743 pregnant U.S. women during 2011-2015.
Disclosures: The study was funded by GlaxoSmithKline, and a coauthor of the study is a company employee. Ms. Yland had no disclosures. Dr. Schatz has received research funding from ALK, AstraZeneca, Medimmune, GlaxoSmithKline, and Merck. Dr. Hernandez-Diaz has been a consultant to Boehringer Ingelheim, Roche, and UCB, and has received research funding from GlaxoSmithKline, Lilly, and Pfizer.
Yland J et al. J Allergy Clin Immunol. 2019 Feb;143:AB422.